---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-013334"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:12:15.011891+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Contineum Therapeutics appoints Timothy Watkins as CMO and Head of Development

## Summary
- Dr. Watkins appointed Chief Medical Officer effective April 28, 2025, succeeding Dr. Stephen Huhn.
- He previously served as VP and Therapeutic Area Head for Inflammation at Gilead Sciences.
- Company plans to start Phase 2 proof-of-concept trial in IPF in H2 2025.
- Received time-based option for 260,000 shares vesting over 42 months and performance-based option for 26,000 shares.
- Grants are inducement awards under Nasdaq Listing Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001437749-25-013334
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925013334/0001437749-25-013334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925013334/cont20250422_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-013334
- JSON: https://secwatch.observer/filing/0001437749-25-013334.json
- Plain text: https://secwatch.observer/filing/0001437749-25-013334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.